Global in-vitro toxicology testing Market value is expected to reach USD 35712 Million by 2023 from USD 18418 Million in 2018, growing at a CAGR of 14.16% for the next five years 2018-2023. In-vitro toxicology testing is the scientific analysis of toxic effects produced by chemical substances on cultured mammalian cells or bacteria. Toxicity testing is very essential in drug discovery as identifies the toxic effects of the new compound in the early stages of drug discovery. This early detection of toxicity reduces the development cost and time.
Increasing technological advancements, rising research & development in cell culture, growing demand for in-vitro toxicology tests over the conventional in-vivo tests, increasing awareness towards toxicity testing studies, rising health-consciousness amongst individuals, growing economic status in emerging nations, existence of favorable regulatory authorities for toxicology testing using the in-vitro tests are driving the growth of in-vitro toxicology testing market. However, scarcity of in-vitro models to detect immunostimulation & autoimmunity, lack of predictive ability of in vitro testing over in vivo testing, technological advancements limiting the use & decreasing adoption rate are the major factors that restrain the growth of in-vitro toxicology testing market.
In-vitro toxicology testing Industry segment-level analysis
Global in-vitro toxicology testing market is segmented based on the product, type, toxicity endpoints & tests, technology, method, and industry. Based on product, the market is further sub-segmented as assays, reagent & labware, and service. Assays segment is estimated to command the largest share of global in-vitro toxicology testing market by product in 2018. Based on the type, the market is segmented as ADME, dose, and toxic substance.
Toxicity endpoints & tests are further segmented as systemic toxicity, dermal toxicity, carcinogenicity, ocular toxicity, skin sensitization & irritation, genotoxicity, neurotoxicity, and organ toxicity. Systemic toxicity is estimated to command the largest share of global in-vitro toxicology testing market by toxicity endpoints & tests in 2016. Technology is further segmented into OMICS technologies & cell culture technology.
in-vitro toxicology testing market segmentation, By the method, the market is segmented as in-silico method, biochemical assays, cellular assays, and ex vivo models. In-silico method is estimated to command the largest share of global in-vitro toxicology testing market by method in 2016. The market, by industry, is sub-segmented as cosmetics & household products, pharmaceutical, diagnostics, chemical, & food. The cosmetics & household products industry is estimated to account for the largest market share of global in-vitro toxicology testing market by industry in 2016.
On the basis of geographical region, the global in-vitro toxicology testing market is segmented as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Europe is estimated to account for the largest share of 32.5% of the global in-vitro toxicology testing market in 2016, whereas Asia-Pacific is estimated to grow at the highest CAGR of 16.10% during the forecast period 2018-2023
In-vitro toxicology testing market leaders
The key players in global in-vitro toxicology testing market include, Covance, Inc. (A subsidiary of LabCorp) (U.S.), Agilent Technologies, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Eurofins Scientific SE (Luxembourg), General Electric Company (U.S.), BioReliance, Inc. (U.S.), Charles River Laboratories International, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Catalent (U.S.), and Cyprotex (U.K.), among others.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 Product
5.1.1 Introduction
5.1.2 Assays
5.1.3 Reagents & Labware
5.1.4 Services Growth Hormone Therapy
5.2 Type
5.2.1 Introduction
5.2.2 ADME (Absorption, Distribution, Metabolism, and Excretion)
5.2.3 Dose
5.2.4 Toxic Substance
5.3 Toxicity Endpoints & Tests
5.3.1 Introduction
5.3.2 Systemic Toxicity
5.3.3 Dermal Toxicity
5.3.4 Carcinogenicity
5.3.5 Ocular Toxicity
5.3.6 Skin Sensitization & Irritation
5.3.7 Genotoxicity
5.3.8 Neurotoxicity
5.3.9 Organ Toxicity
5.3.10 Other Toxicity Endpoints & Tests
5.4 Technology
5.4.1 Introduction
5.4.2 OMICS Technologies
5.4.3 Cell Culture Technology
5.4.4 High-Throughput Technologies
5.4.5 Molecular Imaging Technologies
5.5 Method
5.5.1 Introduction
5.5.2 In-Silico Methods
5.5.3 Biochemical Assays
5.5.4 Cellular Assays
5.5.5 Ex-Vivo Models
5.6 Industry
5.6.1 Introduction
5.6.2 Cosmetics and Household Products
5.6.3 Diagnostics
5.6.4 Pharmaceuticals
5.6.5 Food Industry
5.6.6 Chemicals
6.1 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.2 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.3 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.4 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.4 Rest of Latin America
6.5 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 South Africa
6.5.4 Rest of Middle East & Africa
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 Covance, Inc. (A subsidiary of LabCorp) (U.S.)
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Agilent Technologies, Inc. (U.S.)
8.3 Bio-Rad Laboratories, Inc. (U.S.)
8.4 Eurofins Scientific SE (Luxembourg)
8.5 General Electric Company (U.S.)
8.6 BioReliance, Inc. (U.S.)
8.7 Charles River Laboratories International, Inc. (U.S.)
8.8 Thermo Fisher Scientific, Inc. (U.S.)
8.9 Catalent (U.S.)
8.10 Cyprotex (U.K.)
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
